GenomeRNAi - a database for RNAi phenotypes and reagents
TitleScreen TitleAssayBiomodelSpecies
RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Bauer et al. (2010) Combinatorial effect with paclitaxel (1) Viability (synthetic lethal)HeLaH. sapiens

Abstract

Paclitaxel is a widely used drug in the treatment of patients with locally advanced and metastatic breast cancer. However, only a small portion of patients have a complete response to paclitaxel-based chemotherapy, and many patients are resistant. Strategies that increase sensitivity and limit resistance to paclitaxel would be of clinical use, especially for patients with triple-negative breast cancer (TNBC).

Screen details


Stable Id: GR00179-A-1
Screen title: Combinatorial effect with paclitaxel (1)
Assay: Viability (synthetic lethal)
Method: Alamar Blue
Scope: Selected genes
Screen type: Cell-based
Species: Homo sapiens
Biosource: Cell line
Biomodel: HeLa
Library: OpenBiosystems, pGIPZ shRNAmir plasmid library
Reagent type: shRNA
Score type: Sensitivity index
Cutoff: > 0.078 (> 3 shRNAs) OR > 0.15 (<= 3 shRNAs)
Notes: